Failure of treatments based on the cytokine storm theory of sepsis: Time for a novel approach

Immunotherapy

Volumn 5, Issue 3, 2013, Pages 207-209

  Giamarellos Bourboulis, Evangelos J ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

clarithromycin; immunomodulation; immunoparalysis; sepsis

Indexed keywords

CLARITHROMYCIN; PLACEBO; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; SEPSIS; TREATMENT FAILURE;

ANTIBODIES; CYTOKINES; HUMANS; IMMUNOMODULATION; INFLAMMATION; SEPSIS;

EID: 84874602586     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.8     Document Type: Review

References (12)

1. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34(6), 1589-1596 (2006).
2. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34(8), 1084-1093 (2002).
3. Ranieri VM, Thompson BT, Barie PS et al. Drotrecoginalfa (activated) in adults with septic shock. N. Engl. J. Med. 366(22), 2055-2064 (2012).
4. Gogos C, Kotsaki A, Pelekanou A et al. Early alterations of the innate and adaptive immune statuses is sepsis according to the type of underlying infection. Crit. Care 14(3), R96 (2010).
5. Cruz DN, Antonelli M, Fumagalli R et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301(23), 2445-2452 (2009).
6. Rivers EP, Jaehne AK, Nguyen HB et al. Early biomarker activity in severe sepsis and septic shock and a contemporary review of immunotherapy trials: not a time to give up, but to give it earlier. Shock 39(2), 127-137 (2013).
7. Giamarellos-Bourboulis EJ, van de Veerdonk F, Mouktaroudi M et al. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit. Care 15(1), R27 (2011).
8. Boomer JS, To K, Chang KC et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306(23), 2594-2605 (2011).
9. Martin-Loeches I, Lisboa T, Rodriguez A et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 36(4), 612-620 (2010).
10. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin. Infect. Dis. 46(8), 1157-1164 (2008).
11. Spyridaki A, Raftogiannis M, Antonopoulou A et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob. Agents Chemother. 56(7), 3819-3825 (2012).
12. Leentjens J, Kox M, Koch RM et al. Reversal of immunoparalysis in humans in vivo. Am. J. Respir. Crit. Care Med. 186(9), 838-845 (2012).